E-Pharmacies To Seek Legal Recourse As Madras High Court Bans Online Sale Of Medicines
Hours after the Madras High Court issued a ban on the online sale of medicines until the Centre notifies rules, e-pharmacy companies such as NetMeds, PharmEasy and Midlife plan to appeal the court against the ban.
The court on Monday, which asked the central government to finalise regulations by Jan. 31, later gave an extension till 10:30 am on Dec. 20, after which the ban will take into effect, according to the revised order seen by BloombergQuint.
The judgment comes days after Delhi High Court prohibited e-pharmacies—that have raised over $100 million in funding this year—from selling medicines and asked competent authorities to enforce the ban on online sales. The court had given online pharmacies four weeks to file a counter affidavit.
Over 1 million families use e-pharmacies a month, Dharmil Seth, the co-founder of PharmEasy, told BloombergQuint over the phone. “Today, the customer appreciates the benefits of affordable and easily accessible medicines via online platforms. We welcome regulation and are waiting for the draft to be released soon, but it shouldn't impact customers and especially the senior citizens that rely on platforms such as ours to purchase medicine online,” he said. “We will be applying for a stay tomorrow.”
Pradeep Dadha, founder and chief executive officer of Netmeds.com, too, said that he would pursue seek legal remedy. “We would be filing an appeal and taking the required recourse available under the law,” Dadha said in emailed response to BloombergQuint.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Swiggy vs Eternal: Food Delivery's Two Rivals Are No Longer In The Same Race
Eternal is building a private AI assistant, dark.ai. Swiggy is still working out how to make Instamart pay, with an operating loss of Rs 895 crore in the July-September quarter while Blinkit stayed profitable.
-
Where You Live Shapes How You Get To Work | The Reason Why
Two-wheelers are the most popular way to get to work in India, accounting for nearly 43% of workplace commutes.
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.
-
You May Inherit The Business. You Must Earn Its Credibility.
Succession tests the founder's ability to share authority as much as it tests the next generation's readiness to assume it.
-
Signing Deals Is One Thing; Making Them Work Is Another | The Week In Whys
Sometimes, things don't turn out as planned. Indian companies have lost some bids to rivals, some projects won't produce until 2030.
-
FOMC Wall, PERM Suspension, Hospital Stocks | Talking Points This Week
A PERM suspension would directly affect green-card sponsorship rather than H-1B visas, so the near-term earnings impact could remain relatively limited. The key question is whether this marks a new phase in US scrutiny of Indian IT.